Lower adropin expression is associated with oxidative stress and severity of nonalcoholic fatty liver disease
Abstract
Background & aims Adropin has been reported to be involved in metabolic disorders, including nonalcoholic fatty liver disease (NAFLD). However, the clinical relevance of adropin expression to the histological severity of NAFLD is unclear. This study aimed to investigate adropin expression in biopsy-proven NAFLD patients.Methods This case-control study enrolled a total of 109 participants, including 15 normal histological controls, 26 nonalcoholic fatty liver (NAFL), 21 nonalcoholic steatohepatitis (NASH) subjects and B-ultrasound NAFLD-free normal controls matched to the cases based on age and sex (the case:control ratio was 1:1). Liver biopsies were obtained and histological characteristics were assessed. Primary murine hepatocytes were isolated from C57BL/6J mice and incubated with doses of palmitate to induce oxidative stress.Results The serum adropin level in NASH patients was 9.99 ± 5.51 ng/ml, significantly lower than that in B-ultrasound normal controls (22.70 ± 6.32 ng/ml), histological normal controls (21.93 ± 6.63 ng/ml) and NAFL patients (17.82 ± 6.90 ng/ml). Serum adropin levels were negatively correlated with the histological severity of NAFLD. The lower serum adropin level predicted NASH (area under the ROC curve: 87.1%). Adropin expression in serum and liver was also negatively associated with hepatic MDA and serum 8-iso-PGF2α levels. Furthermore, palmitate rather than oleate induced oxidative stress in a dose-dependent manner with a gradient decrease in adropin expression in primary murine hepatocytes. Adropin overexpression or treatment ameliorated palmitate-induced oxidative stress in hepatocytes.Conclusions Circulating adropin was inversely associated with the oxidative stress and histological severity of NAFLD. It may play an important role in the development of NAFLD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Lower adropin expression may play an important role in the progression of NAFLD to severe NASH.
“It is also negatively related to the pathological changes in NAFLD, suggesting that the lower adropin expression may play an important role in the progression of NAFLD to severe NASH.”
From Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions (2021) · cites this paper as [113]
Adropin is negatively related to the pathological changes in NAFLD.
“It is also negatively related to the pathological changes in NAFLD, suggesting that the lower adropin expression may play an important role in the progression of NAFLD to severe NASH.”
From Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions (2021) · cites this paper as [113]
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · see citing works
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285 · see citing works
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119 · see citing works
The utility of radiological imaging in nonalcoholic fatty liver disease
Saadeh, S. N., Younossi, Z. M., Remer, E. M., Gramlich, T., Ong, J. P., Hurley, M. E., Mullen, K. D., Cooper, J. N., & Sheridan, M. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.35354 · Cited by 2,112 · see citing works
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
Diehl, A. M., & Day, C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1503519 · Cited by 1,283 · see citing works
Nonalcoholic Fatty Liver Disease: Pathology and Pathogenesis
Tiniakos, D. G., Vos, M. B., & Brunt, E. M. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102132 · Cited by 870 · see citing works
Mitochondrial dysfunction in Nash: causes, consequences and possible means to prevent it
Begriche, K., Igoudjil, A., Pessayre, D., & Fromenty, B. (2006) · Mitochondrion · doi:10.1016/j.mito.2005.10.004 · Cited by 753 · see citing works
Sumida, Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i2.475 · Cited by 693 · see citing works
Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
Mota, M., Banini, B. A., Cazanave, S. C., & Sanyal, A. J. (2016) · Metabolism · doi:10.1016/j.metabol.2016.02.014 · Cited by 570 · see citing works
Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease
Joseph, A. E. A., Saverymuttu, S. H., Al‐Sam, S., Cook, M. G., & Maxwell, J. D. (1991) · Clinical Radiology · doi:10.1016/s0009-9260(05)80350-2 · Cited by 514 · see citing works
Kumar, K. G., Trevaskis, J. L., Lam, D. D., Sutton, G. M., Koza, R. A., Chouljenko, V. N., Kousoulas, K. G., Rogers, P. M., Kesterson, R. A., Thearle, M. S., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.10.011 · Cited by 511 · see citing works
Pathology of nonalcoholic fatty liver disease
Brunt, E. M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.21 · Cited by 484 · see citing works
Natural history of nonalcoholic steatohepatitis: A longitudinal study of repeat liver biopsies
Fassio, E., �lvarez, E., Dom�nguez, N., Landeira, G., & Longo, C. (2004) · Hepatology · doi:10.1002/hep.20410 · Cited by 470 · see citing works
Lomonaco, R., Ortiz‐Lopez, C., Orsak, B., Webb, A., Hardies, J., Darland, C., Finch, J., Gastaldelli, A., Harrison, S. A., Tio, F. O., et al. (2011) · Hepatology · doi:10.1002/hep.25539 · Cited by 461 · see citing works
Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis
Spahis, S., DELVIN, E. E., Borys, J.-M., & Levy, E. H. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6776 · Cited by 386 · see citing works
Fang, Y., Chen, H., Wang, C., & Liang, L. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i27.2974 · Cited by 383 · see citing works
Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging
Dyson, J. K., Anstee, Q. M., & McPherson, S. (2013) · Frontline Gastroenterology · doi:10.1136/flgastro-2013-100403 · Cited by 358 · see citing works
Krawczyk, M. J., Rau, M., Schattenberg, J. M., Bantel, H., Pathil, A., Demir, M., Kluwe, J., Boettler, T., Lammert, F., & Geier, A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p067454 · Cited by 204 · see citing works
Pickhardt, P. J., Park, S. H., Hahn, L., Lee, S., Bae, K. T., & Yu, E. S. (2011) · European Radiology · doi:10.1007/s00330-011-2349-2 · Cited by 194 · see citing works
New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
Méndez‐Sánchez, N., Cruz-Ramón, V., Ramírez-Pérez, O., Hwang, J. P., Barranco-Fragoso, B., & Córdova‐Gallardo, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072034 · Cited by 174 · see citing works
Severgnini, M., Sherman, J., Sehgal, A., Narayanannair, J. K., Aubin, J., Wang, G., Zhang, L., Peng, C. G., Yucius, K., Butler, J. S., et al. (2011) · Cytotechnology · doi:10.1007/s10616-011-9407-0 · Cited by 169 · see citing works
Chen, X., Xue, H., Fang, W., Chen, K., Chen, S., Yang, W., Shen, T., Chen, X., Zhang, P., & Ling, W. (2018) · Redox Biology · doi:10.1016/j.redox.2018.101068 · Cited by 141 · see citing works
Self-citationAdropin as A Fat-Burning Hormone with Multiple Functions—Review of a Decade of Research
Jasaszwili, M., Billert, M., Strowski, M. Z., Nowak, K. W., & Skrzypski, M. (2020) · Molecules · doi:10.3390/molecules25030549 · Cited by 120 · see citing works
Zang, H., Jiang, F., Cheng, X., Xu, H. W., & Hu, X. (2018) · Endocrine Journal · doi:10.1507/endocrj.ej18-0060 · Cited by 92 · see citing works
Self-citationSayın, O., Tokgöz, Y., & Arslan, N. (2014) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2013-0296 · Cited by 82 · see citing works
Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease
Pοlyzos, S. A., & Mantzoros, C. S. (2013) · Metabolism · doi:10.1016/j.metabol.2013.10.010 · Cited by 72 · see citing works
A comparison of methods for the measurement of 8-isoPGF 2 α : a marker of oxidative stress
Smith, K. A., Shepherd, J., Wakil, A., & Kilpatrick, E. S. (2011) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2010.010151 · Cited by 59 · see citing works
Adropin deficiency worsens HFD-induced metabolic defects
Chen, S., Zeng, K., Liu, Q., Guo, Z., Zhang, S., Chen, X., Lin, J., Wen, J., Zhao, C., Lin, X., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.362 · Cited by 56 · see citing works
Self-citationA novel peptide adropin in cardiovascular diseases
Li, L., Xie, W., Zheng, X., Yin, W., & Tang, C. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.12.010 · Cited by 52 · see citing works
Chen, J., Zheng, M., Liu, J., Luo, Y., Yang, W., Yang, J., Liu, J., Jingxing, Z., Xu, C., Zhao, F., et al. (2019) · Obesity · doi:10.1002/oby.22627 · Cited by 46 · see citing works
Serum Adropin Levels Are Reduced in Adult Patients with Nonalcoholic Fatty Liver Disease
Kutlu, O., Altun, Ö., Dikker, O., Aktaş, H. Ş., Özsoy, N., Arman, Y., Çil, E. Ö., Özcan, M., Yoldemir, Ş. A., Akarsu, M., et al. (2019) · Medical Principles and Practice · doi:10.1159/000500106 · Cited by 44 · see citing works
Zheng, J., Liu, M., Chen, L., et al. (2019) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2018.07.09 · Cited by 32 · see citing works
Chang, J., Chu, N., Lin, F., et al. (2017) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2017.03.001 · Cited by 21 · see citing works
NASH, from diagnosis to treatment: Where do we stand?
Harrison, S. A. (2015) · Hepatology · doi:10.1002/hep.28275 · Cited by 16 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Inter-organ crosstalk during development and progression of type 2 diabetes mellitus
Xourafa, G., Korbmacher, M., & Roden, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00898-1 · Cited by 274 · see citing works
Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions
de Oliveira dos Santos, A. R., de Oliveira Zanuso, B., Miola, V. F. B., Barbalho, S. M., Santos Bueno, P. C., Flato, U. A. P., Detregiachi, C. R. P., Buchaim, D. V., Buchaim, R. L., Tofano, R. J., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052639 · Cited by 189 · see citing works
- Authors
- Chen, X., Sun, X., Shen, T., Chen, Q., Chen, S., Pang, J., Mi, J., Tang, Y., You, Y., Xu, H., & Ling, W.
- Affiliations
- Sun Yat-sen University (CN)
- Guangdong Pharmaceutical University (CN)
- Corresponding author
- Ling, Wenhua
- Venue
- Free Radical Biology and Medicine
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 160
- Pages
- 191-198
- ISSN
- 0891-5849 (ISSN-L)
- OpenAlex
- W3049733492
- Cited by
- 30
- References
- 34
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 4
- FWCI
- 2.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Free Radical Biology and Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China
- Guangzhou Research Collaborative Innovation Projects
- Topics
- Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Epidemiology › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- adropin, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, oxidative stress, histological severity, malondialdehyde, 8-isoprostane, palmitate, hepatocytes, biomarkers, liver biopsy
- MeSH terms
- Animals, Humans, Liver, Mice, Inbred C57BL, Biomarkers, Case-Control Studies, Oxidative Stress, Intercellular Signaling Peptides and Proteins, Mice, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
